dihydrofolate reductase inhibitors

dihydrofolate reductase inhibitors

Drugs that block the action of DIHYDROFOLATE REDUCTASE. Some of the drugs that inhibit this enzyme can, as in the case of METHOTREXATE, be used as anticancer drugs. Some of them have little effect on the human enzyme but a strong effect on the dihydrofolate reductases of bacterial and other parasites. Trimetrexate (Neutrexin) is a case in point; it is active against Pneumocystis carinii .
Mentioned in ?
References in periodicals archive ?
Evolution of the bacterial dihydrofolate reductase inhibitors.
Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. (Perspectives)
One group of such agents is dihydrofolate reductase inhibitors, which block the conversion of folate to its more active metabolites.
Folic Acid Antagonists Raise the Risk of a Variety of Birth Defects
Methods: We assessed exposure to folic acid antagonists that act as dihydrofolate reductase inhibitors and to certain antiepileptic drugs in 3,870 infants with cardiovascular defects, 1,962 infants with oral clefts, and 1,100 infants with urinary tract defects, and also in 8,387 control infants with malformations, the risk of which is not reduced after vitamin supplementation.
Folic Acid Antagonists during Pregnancy and the Risk of Birth Defects
Key classes of mechanism of action includes Interleukin inhibitors, Kinase inhibitors, cytokine targetters, TNF targetters, C5a receptor antagonists, Cathepsin inhibitors, Histone deacetylase inhibitors (HDAC) inhibitors, Janus Kinase 3(JAK-3) inhibitors, CD4 inhibitors, p38 kinase inhibitors, Dihydrofolate Reductase inhibitors, cyclooxygenase (COX) inhibitors, Chemokine receptor antagonists, Glucocorticoid antagonists, Dihydroorotate dehydrogenase(DHODH) inhibitors, and combination therapies.
Research and Markets: Rheumatoid Arthritis - Pipeline Assessment and Market Forecasts to 2017
In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.
Global Antibacterials Market Set to Grow to Over US$45 Billion by 2012

Medical browser ?
Full browser ?